Harbor Capital Advisors, Inc. Nektar Therapeutics Transaction History

Harbor Capital Advisors, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2023 Oct 20, 2023	SELL	$0.51 - $1.05 $16,844 - $34,680	-33,029 Reduced 39.89%	49,769 $29,000
Q2 2023 Jul 11, 2023	BUY	$0.53 - $1.03 $43,882 - $85,281	82,798 New	82,798 $48,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.